Overview:
IGB offers the Yourgene® DPYD assay which is a simple genotyping test which uses ARMS (Amplification-Refractory Mutation System) technology for the rapid detection of the six clinically relevant variants which lead to reduced dihydropyrimidine dehydrogenase enzyme (DPD) efficiency. This enzyme is encoded by the DPYD gene. 5-fluoracil (5-FU) is a chemotherapy agent used to treat a range of cancers including colorectal, head and neck, breast, pancreatic and stomach cancer. Identifying patients with DPD deficiency prior to commencing 5-FU chemotherapy is critical to avoid potentially fatal adverse drug reactions.
Features:
CE-IVDR Certified
• One of the first IVDR certified assays for pharmacogenomics screening providing a high quality, fully validated product that requires minimal validation to fit into your workflow
Rapid Workflow
• Post-DNA extraction, the rapid workflow is completed in less than 4 hours
• Rapid results are available to a clinican within one working day
Two Tube Assay
• Simple to use; just add DNA
• Minimal hands-on time and fewer reagents to improve economies of testing
Reliable Performance
• Optically balanced primers to maximise ease-of-interpretation and reduce analysis burden
Compatible with ABI 3130/3500/SeqStudio Genetic Analyser Platforms
• Validated on popular sequencing platforms, facilitating ease of adoption
Aligned to clinical guidelines and pathways
• Coverage of clinically actionable variants, as recommended by European Medicines Agency (EMA), European Society for Medical Oncology (ESMO) and Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines
